ArticleFrontiers in oncology2026
Metabolic dynamic score and machine learning: a novel approach to predicting pathological complete response in rectal cancer after neoadjuvant chemoradiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study developed a scoring system based on the dynamic changes in biochemical indicators in advance of and subsequent to neoadjuvant chemoradiotherapy (NCRT) in individuals with locally advanced rectal cancer (LARC). The scoring system, combined with other clinical features, was used to develop a machine learning (ML) model aimed at predicting a pathological complete response (pCR). Methods: A review of earlier data was performed on the data of 1300 patients with LARC treated at Center1 and Center 2. To determine factors linked to pCR and create the scoring system, uni and multivariate logistic regression analyses were conducted. The development of predictive models involved the use of 10 ML methods, while model performance was evaluated using the area under the receiver operating characteristic curve (AUC), area under the precision-recall curve (AUPRC), decision curve analysis, and calibration curves. Additionally, SHapley Additive exPlanations values were applied to enhance model interpretability. Results: Multivariate analysis identified the MDS, tumor size, clinical T stage, and clinical N stage as independent predictors, which were incorporated into the ML models. Among the 10 ML models, the XGBoost model demonstrated the best and most generalizable predictive performance (training set: AUC = 0.93, AUPRC = 0.732; external validation set: AUC = 0.92, AUPRC = 0.779) and was selected as the optimal model. Conclusion: This study analyzed changes in biochemical indicators pre- versus post-NCRT and developed a promising MDS. By leveraging ML predictive models to estimate pCR, this approach may serve as a convenient tool to support the clinical decision-making process pending further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.